Clinical Trial Update: A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 1]

View source ↗

Summary

Phase 1 trial update of ABBV-453 in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, focusing on adverse events and pharmacokine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• ABBV-453

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING